Achieve Life Sciences Advances Cytisinicline for Nicotine Dependence Treatment at J.P. Morgan Conference
- Achieve Life Sciences develops cytisinicline, aiming for FDA approval to treat nicotine dependence and smoking cessation.
- The company’s New Drug Application (NDA) highlights its successful Phase 3 studies and a PDUFA date of June 20, 2026.
- Achieve is addressing vaping cessation needs, having completed a Phase 2 study and received FDA feedback for cytisinicline.
Achieve Life Sciences Advances in Nicotine Dependence Treatment
Achieve Life Sciences, Inc. is at the forefront of developing innovative solutions for nicotine dependence, focusing on its lead candidate, cytisinicline. The company prepares to showcase its advancements during the upcoming 44th Annual J.P. Morgan Healthcare Conference, where CEO Rick Stewart and senior management will hold one-on-one meetings with investors and industry stakeholders. The discussions will center around Achieve's late-stage cytisinicline program aimed at combating smoking and vaping cessation, alongside strategic plans for the upcoming year. This event is critical for the company, especially following the recent acceptance of its New Drug Application (NDA) by the U.S. FDA, which is a significant milestone in its journey to bring effective treatments to market.
The NDA submission is supported by two completed Phase 3 studies and a safety study, underscoring the efficacy of cytisinicline in addressing nicotine dependence in adults. With a Prescription Drug User Fee Act (PDUFA) date set for June 20, 2026, the potential for cytisinicline to become an FDA-approved treatment for smoking cessation is within reach. The urgency for new therapeutic options is highlighted by the staggering statistics surrounding nicotine use; approximately 29 million adults in the U.S. smoke combustible cigarettes, leading to over eight million deaths globally each year. Moreover, with nearly half a million deaths occurring annually in the U.S. alone, the need for effective cessation aids cannot be overstated, particularly as the vaping trend grows among the youth demographic.
Achieve Life Sciences has also made significant progress in addressing vaping cessation, having completed a Phase 2 study and receiving positive feedback from the FDA during an end-of-Phase 2 meeting. The rising prevalence of e-cigarette use, especially among middle and high school students—with an estimated 1.6 million reported users in 2024—further emphasizes the critical need for targeted interventions. Currently, there are no FDA-approved treatments specifically for e-cigarette cessation, creating a vital gap in available resources. Cytisinicline, a plant-based alkaloid that interacts with nicotinic acetylcholine receptors, demonstrates promise in helping individuals overcome nicotine addiction, making it a compelling option for those seeking to quit smoking or vaping.
In addition to its conference participation, Achieve Life Sciences invites interested parties to schedule meetings through its Investor Relations team. The company's engagement at the J.P. Morgan Healthcare Conference marks a strategic opportunity to highlight its commitment to addressing nicotine dependence and advancing public health initiatives. As the landscape of nicotine addiction evolves, Achieve’s innovative approach stands to make a significant impact in the fight against this pervasive health challenge.